Sucampo Pharmaceuticals — Q2 2016 Earnings Presentation
22 slides from Sucampo Pharmaceuticals's earnings presentation, Aug 3, 2016
Slide 1: Second Quarter 2016 Corporate Update and Financial Results
€ $ SUCAMPO_ The Science of Innovati Second Quarter 2016 Corporate Update and Financial Results August 3, 2016
Slide 2: Introductions and Forward-Looking Statements
Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations & Corporate Affairs
Slide 3: Agenda
Agenda $ sucampo_ Pipeline Update Peter Kiener, D. Phil Closing Remarks Peter Greenleaf
Slide 4: Forward Looking Statement
Forward Looking Statement $ sucampo This presentation contains "forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. ‘These statements are based on management's current expectations and involve risks and uncertainties, which may cause results t
Slide 5: Q2 2016 - Peter Greenleaf, Chairman and CEO
Q2 2016 Corporate Update Peter Greenleaf, Chairman and CEO
Slide 6: Continued Progress Against Strategic Objectives
Strong Financial Performance e Continued Progress Against Strategic Objectives 2 SUCAMPO. 1. Continue to deliver outstanding financial performance 2. Continue to prioritize and progress our pipeline 3. Continue to transform company for sustained mid- and long-term growth
Slide 7: Solid Q2 Overall Financial Results
Solid Q2 Overall Financial Results $ sucampo REVENUE * Overall revenue grew 49% YoY to $52.0M - Increased royalties for AMITIZA in the U.S. - Sales of AMITIZA in Japan — Inclusion of RTU results + Revenue grew 9% when excluding $13.8M RTU-related revenue EARNINGS* + Adjusted Net Income grew 2% YoY t
Slide 8: Strong U.S. AMITIZA Performance
Strong U.S. AMITIZA Performance $ sucampo Takeda’s AMITIZA net sales for royalty calculation purposes — Q2 grew 15% YoY to $102.0M Royalty revenue grew 16% YoY to $18.7M - Drivers: price, volume, inventory Overall U.S. revenue includes $12.4M of AMITIZA product sales to Takeda AMITIZA TRx — Q2IMS: ~
Slide 9: AMITIZA U.S. Growth Trends
AMITIZAU.S. Growth Trends $ sucampo + Takeda aggressively driving brand through sales, marketing, and managed care + Patient access prioritized - Coverage of ~90% of all lives across all payor channels - Key access wins (effective 1/1/17): + Added back to CVS Caremark preferred formulary + Elevated
Slide 10: Japan AMITIZA Performance
Japan AMITIZA Performance $ sucampo + Sucampo Q2 revenue: $14.6M — 1H16 revenue growth of 14% + Revenue essentially flat QoQ due to timing of shipments to Mylan — Strong underlying market growth + Mylan promotion priorities - Focus on high-volume/high-decile physicians - Digital disease awareness an
Slide 11: 2016 Guidance Reaffirmed
2016 Guidance* Reaffirmed $ sucamPpo_ + Total revenue: $195 million to $205 million + Adjusted net income: $45 million to $50 million + Adjusted EPS: $0.97 to $1.07 « Adjusted EBITDA: $100 million to $105 million * Guidance excludes amortization of acquired intangibles of approximately $17.6 million
Slide 12: Pipeline Progress: Upcoming Milestones
Pipeline Progress: Upcoming Milestones Expected Timing Product | Event AMITIZA, (lubiprostone) AMITIZA (ubiprostone) AMITIZA (lubiprostone) AMITIZA (ubiprostone) Initiation of Phase 3 pivotal alternate formulation in adults Top-line data from Phase 3 pivotal PFC (6-17 years) ‘Top-line data from Phas
Slide 13: Pipeline Update
Pipeline Update Peter Kiener, D.Phil, CSO
Slide 14: Prioritized and Diversified Product Pipeline
Prioritized and Diversified Product Pipeline $ sucampo Program Target First Indication | Leal | aie Approval Gi/Metabolic! ’ 7 AMITIZA ica Pediatric functional constipation PS r 2017 Lubiprostone Pediatric Deen : Sean Microparticle cice functional constipation (1); P38 018(1); 2019 (1); etoeartet “a
Slide 15: Financial Update
Financial Update Andrew Smith, CFO
Slide 16: Q2 Revenue
$ sucampo Q2 Revenue 60.0 40.0 S300 = 20.0 10.0 00 AMITIZA US Royalty AMITIZA Japan Other Q2 2016 16 02.2015 R-Tech Inclusion
Slide 17: Q2 Adjusted Net Income
$ sucampo Q2 Adjusted Net Income 15.0 = a) . EH $ Million Other 22016 7 00 Revenue Margin TaxRate —StockExpense _Interest 02.2015 RTU
Slide 18: Q2 Adjusted EBITDA
Q2 Adjusted EBITDA $ sucampo 30.0 250 — 20.0 10.0 }— - 50 00 022015 R-Tech Inclusion Revenue contribution Other a2 2016 8
Slide 19: Key Balance Sheet Items
Key Balance Sheet Items $ sucampo |_item | As of 6/30/16 As of 12/31/15 Cash, Cash Equivalents and $154.9M ($8.6) $163.5M Restricted Cash Total Debt ($224.1M) $28.3M ($252.4M) Net Debt ($69.2M) $19.7M ($88.9M) 19
Slide 20: Closing Remarks
Closing Remarks Peter Greenleaf, Chairman and CEO
Slide 21: 2016 Areas of Focus
2016 Areas of Focus $ sucampo 1. Deliver outstanding financial performance 2. Advance pipeline programs 3. Evaluate and execute on additional opportunities for growth 24
Slide 22: Q&A Session
Q&A Session
Sucampo Pharmaceuticals — Q2 2016 Earnings Presentation on 6ix